

To: Beth Balderston <[info@cervicalcanceraction.org](mailto:info@cervicalcanceraction.org)>  
From: Cervical Cancer Action  
From Email: [info@cervicalcanceraction.org](mailto:info@cervicalcanceraction.org)  
Subject: Cervical Cancer Action News Brief  
Preheader:

Trouble viewing this email? [Read it online](#)



## Cervical Cancer Action News Brief | April 2014

*News and views of interest to our community*

---

### Cervical Cancer Action: 2007 to 2014 . . . and beyond

Seven years after our founding and eight years after HPV vaccines first became available, Cervical Cancer Action—the first global partnership aimed at reducing cervical cancer in high-burden, low-income countries—offers a snapshot of our [accomplishments to date](#) and our vision of the work ahead.

### CCA membership survey coming soon—let us know what you think!

Please be on the lookout next month for an email from Cervical Cancer Action asking a few short questions about your experience with CCA products such as these News Briefs, our maps, webinars, issue briefs, and report card.

We would love to hear from you so that we can improve our service!

### KAP Survey on Cervical Cancer and HPV in Central America

Findings from the first-ever Cervical Cancer and HPV knowledge, attitudes, and practices (KAP) survey in Central America has been published. The study was conducted in El Salvador as part of Union for International Cancer Control's (UICC) Cervical Cancer Initiative. Findings will assist the Salvadorian Ministry of Health to develop key communication strategies to support national cervical cancer prevention and control efforts and eventual roll-out of HPV vaccine in the country.

The [Spanish version of the report](#) is now available. The English version will be available next month.

For more information, please contact [Melissa Rendler-Garcia](#), UICC Latin America Regional Advisor.

### WHO SAGE recommends two-dose HPV vaccine schedule

In our last CCA News Brief we shared the good news that the European Commission had granted marketing authorization for GlaxoSmithKline's Cervarix® as a two-dose schedule for girls aged 9 to 14.

Since then, Sanofi Pasteur MSD [announced](#) that its quadrivalent HPV vaccine, Gardasil®, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the use of a two-dose schedule in 9 to 13 year-old adolescent girls and boys.

Also since then, the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) [has recommended](#) a two-dose schedule for girls, if vaccination is initiated prior to 15 years of age. A three-

dose schedule remains necessary if immunization is initiated after a girl's 15th birthday. And a three-dose schedule (i.e., at 0, 1–2, and 6 months) remains recommended for immunocompromised individuals, including those known to be infected with HIV.

## WHO's HPV vaccine communication guidance document now available in French

The WHO publication, [HPV Vaccine Communication: Special considerations for a unique vaccine](#) is now available in French as [Communication sur le vaccin contre le PVH: Considérations particulières pour un vaccin unique](#).

## 2014 World Cancer Congress, Melbourne, Australia, 3–6 December, 2014

This year's [World Cancer Congress](#) theme, "Joining Forces: Accelerating Progress" will emphasize the impact that can be realized by consistently and energetically applying what we know, rather than waiting for possible future breakthroughs to change the landscape. Participants will leave with an increased understanding of successful interventions in prevention, diagnosis and care, and supportive and palliative care. The 2014 Congress marks the first time that submissions are open not only for scientific papers, but also for practice, policy, advocacy, or fundraising reports.

---

---

### Cervical Cancer Action Governing Council



### Secretariat



[info@cervicalcanceraction.org](mailto:info@cervicalcanceraction.org) | [www.cervicalcanceraction.org](http://www.cervicalcanceraction.org)

This email is intended for [info@cervicalcanceraction.org](mailto:info@cervicalcanceraction.org).  
[Update your preferences](#) or [Unsubscribe](#)

delivered by  
 Campaigner